Anbio Biotechnology (NNNN) Current Assets (2023 - 2025)

Anbio Biotechnology has reported Current Assets for 3 years, with the latest figure at $30.2 million in Q4 2025.

• On a quarterly basis, Current Assets rose 63.17% year-over-year to $30.2 million in Q4 2025; TTM through Dec 2025 was $30.2 million, a 63.17% increase from a year earlier, with the FY2025 full-year figure at $30.2 million, up 63.17% from the prior year.
• Current Assets was $30.2 million for Q4 2025 at Anbio Biotechnology, up from $27.7 million in the prior quarter.
• The five-year high for Current Assets was $30.2 million in Q4 2025, with the low at $15.7 million in Q4 2023.
• Average Current Assets over 3 years is $23.1 million, with a median of $23.1 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Current Assets advanced 17.68% in 2024, then soared 63.17% in 2025.
• Over 3 years, Current Assets stood at $15.7 million in 2023, then gained by 17.68% to $18.5 million in 2024, then jumped by 63.17% to $30.2 million in 2025.
• The last three Current Assets figures came in at $30.2 million (Q4 2025), $27.7 million (Q2 2025), and $18.5 million (Q4 2024), per Business Quant data.